Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Short term Debt (2018 - 2023)

X4 Pharmaceuticals' Short term Debt history spans 5 years, with the latest figure at $764000.0 for Q2 2023.

  • For Q2 2023, Short term Debt fell 91.12% year-over-year to $764000.0; the TTM value through Jun 2023 reached $764000.0, down 91.12%, while the annual FY2022 figure was $1.3 million, 65.41% up from the prior year.
  • Short term Debt reached $764000.0 in Q2 2023 per XFOR's latest filing, up from $554000.0 in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $14.6 million in Q3 2022 to a low of $554000.0 in Q1 2023.
  • Average Short term Debt over 4 years is $4.0 million, with a median of $2.4 million recorded in 2022.
  • Peak YoY movement for Short term Debt: surged 2009.81% in 2022, then crashed 91.12% in 2023.
  • A 4-year view of Short term Debt shows it stood at $4.2 million in 2019, then plummeted by 80.85% to $795000.0 in 2021, then surged by 65.41% to $1.3 million in 2022, then plummeted by 41.9% to $764000.0 in 2023.
  • Per Business Quant, the three most recent readings for XFOR's Short term Debt are $764000.0 (Q2 2023), $554000.0 (Q1 2023), and $1.3 million (Q4 2022).